ERBB2 and breast cancer: Our previous study demonstrated that bevacizumab combined with chemotherapy significantly increased the rate of pathological response among patients with HER2 negative advanced breast cancer.[14] Li et al[15] recently performed a meta-analysis to investigate bevacizumab combined with chemotherapy in metastatic breast cancer and found that bevacizumab combined with chemotherapy produced a substantial improvement in progression-free survival.